SURVEY DETAILS

TARGET POPULATION

GLG surveyed 70 endocrinologists who treat diabetes and prescribe GLP-1 drugs across US and Europe (UK, Italy, France, Germany and Spain).

What will you learn from this survey?

  • Respondents commented on the current GLP-1 drug prescription scenario including prescription for diabetes vs obesity, line of therapy, age breakdown as well as change in prescription volume over the past one year.
  • The research also assessed the impact of recent suicidal ideation reports and weight gain tendency of GLP-1 drugs on the prescription trends.
  • Lastly, the survey looked into the competitive landscape, comparing GLP-1 drug brands on the basis of growth outlook, cost, reimbursement, patient preference, incidence of side effects and brand recognition.

Examples of findings:

  • Almost nine-in-ten (89%) declare there has been no impact on prescriptions from suicidal ideation reports.
  • While over six-in-ten (64%) state GLP-1R drugs are the second line of therapy for diabetes, over half (54%) declare it is the first line of therapy for obesity.
  • Over three-in-four (77%) endocrinologists saw their prescription volume increase over the past year, among them over one-quarter (26%) stated the increase was 30% or more.

DELIVERABLES

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Ake Sjoholm, Professor of Medicine, Senior Clinical Consultant, University of Gävle.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

SAMPLE QUESTIONS

  • What proportion of your patients have discontinued the treatment after prescription?
  • Approximately, how many GLP-1R agonist drug prescriptions do you plan to make in the next 6 months?
  • Have the recent reports on suicidal ideation had any impact on your prescription of GLP-1R agonist drugs?
  • Weight loss due to GLP-1R agonist drugs, is partly (75-80%) gained back after drug use is stopped. What impact has this had on your prescription?
  • In your view, what would the scenario of GLP-1R agonists drugs be, 5 years from now?
  • In your view, which of following brands of GLP-1R agonist drugs has the best growth outlook in the next 5 years?
  • Please rate the following brands of GLP-1R agonist drugs on the basis of their cost.

ACCESS

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.

 

 

Thank you for contacting GLG, someone will respond to your inquiry as soon as possible.